Should I buy Apollo Hospitals stock in 2025?
Is it the right time to buy Apollo Hospitals?
ScoreApollo Hospitals Enterprise Limited, trading at approximately ₹7,565 (as of 3 July 2025) with a healthy average daily volume of 453,300 shares, stands as a bellwether in India's private healthcare sector. The past year has seen its stock rise over 22%, underpinned by solid quarterly results: revenue up 13% year-on-year and net profit surging 54%. Recent major developments, such as the planned spin-off of digital health and pharmacy operations into a new entity, expansion plans to add 3,500 more beds, and a technology partnership with Microsoft to integrate AI solutions, have further strengthened its strategic outlook without creating excessive volatility. Market sentiment remains upbeat, driven by a 92% buy recommendation rate and consistent 'Strong Buy' technical signals. While its high Price/Earnings ratio (75.2) reflects premium valuation, this is balanced by Apollo's leadership in innovation and operational expansion. In the context of India's fast-growing healthcare market, Apollo's position as a trusted provider, coupled with ongoing investments in technology and geographical reach, sets a constructive backdrop. According to the consensus of 13 leading national and international banks, the near-term target price is set at ₹9,835, supporting a positive stance for consideration.
- ✅Consistent double-digit revenue and profit growth surpassing analyst expectations.
- ✅Strategic spin-off of high-growth digital and pharmacy businesses increases value.
- ✅Aggressive expansion with plans to add 3,500 beds enhancing scale.
- ✅Innovation leadership via AI partnerships, notably with Microsoft.
- ✅Strong brand and dominant presence across 73 hospitals nationwide.
- ❌Premium valuation with high PER demands sustained growth to justify levels.
- ❌Revenue still concentrated mainly within India, exposure to local economic shifts.
Score- ✅Consistent double-digit revenue and profit growth surpassing analyst expectations.
- ✅Strategic spin-off of high-growth digital and pharmacy businesses increases value.
- ✅Aggressive expansion with plans to add 3,500 beds enhancing scale.
- ✅Innovation leadership via AI partnerships, notably with Microsoft.
- ✅Strong brand and dominant presence across 73 hospitals nationwide.
Is it the right time to buy Apollo Hospitals?
- ✅Consistent double-digit revenue and profit growth surpassing analyst expectations.
- ✅Strategic spin-off of high-growth digital and pharmacy businesses increases value.
- ✅Aggressive expansion with plans to add 3,500 beds enhancing scale.
- ✅Innovation leadership via AI partnerships, notably with Microsoft.
- ✅Strong brand and dominant presence across 73 hospitals nationwide.
- ❌Premium valuation with high PER demands sustained growth to justify levels.
- ❌Revenue still concentrated mainly within India, exposure to local economic shifts.
Score- ✅Consistent double-digit revenue and profit growth surpassing analyst expectations.
- ✅Strategic spin-off of high-growth digital and pharmacy businesses increases value.
- ✅Aggressive expansion with plans to add 3,500 beds enhancing scale.
- ✅Innovation leadership via AI partnerships, notably with Microsoft.
- ✅Strong brand and dominant presence across 73 hospitals nationwide.
- What is Apollo Hospitals?
- Apollo Hospitals Stock Price
- Our full analysis of the Apollo Hospitals stock
- How to Buy Apollo Hospitals Stock
- Our 7 tips for buying Apollo Hospitals stock
- The latest news about Apollo Hospitals
- FAQ
- On the same topic
Why trust HelloSafe ?
At HelloSafe, our expert has been tracking the performance of Apollo Hospitals for over three years. Every month, tens of lakhs of users in India trust us to decipher market trends and identify the best investment opportunities. Our analyses are provided for informational purposes and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, paid by Apollo Hospitals.
What is Apollo Hospitals?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | India | Apollo Hospitals is a leading healthcare company in India. |
| 💼 Market | NSE / BSE | Listed on major Indian stock exchanges, ensuring liquidity. |
| 🏛️ ISIN code | INE437A01024 | International identifier for tracking on global platforms. |
| 👤 CEO | Suneeta Reddy | Leadership is recognized for strategic growth and innovation. |
| 🏢 Market cap | ₹1,08,669 crores | Large market cap reflects sector dominance and investor trust. |
| 📈 Revenue | ₹21,150 crores (annualized, FY25) | Strong revenue growth driven by expansion and private demand. |
| 💹 EBITDA | ₹3,060 crores (annualized, FY25) | Consistent operating margin signals sustainable profitability. |
| 📊 P/E Ratio (Price/Earnings) | 75.2 | High P/E highlights high growth expectations and strong demand. |
Apollo Hospitals Stock Price
The price of Apollo Hospitals stock is rising this week. The current share price stands at ₹7,565.00, reflecting a 24-hour increase of ₹124.00 (+1.67%) and a weekly gain of 11.05%. With a market capitalization of ₹1,08,669 crores and an average three-month trading volume of 453,300 shares, Apollo Hospitals enjoys strong investor interest. The stock trades at a P/E Ratio of 75.2, offers a dividend yield of 0.21%, and has a low beta of 0.28. Such resilience and performance highlight both its stability and its long-term growth appeal.
Our full analysis of the Apollo Hospitals stock
Having reviewed Apollo Hospitals’s latest financial results and analysed the stock’s remarkable multi-year performance, we leverage proprietary algorithms that blend financial indicators, technical signals, and rigorous peer benchmarking. Our process synthesises rich datasets from real-time market activity and comprehensive sectoral analysis to inform a dynamic, opportunity-driven perspective. So, why might Apollo Hospitals stock once again become a strategic entry point into the Indian healthcare and innovation sector in 2025?
Recent performance and market context
Apollo Hospitals has continued to outperform peers in the past year, with its stock currently trading at ₹7,565.00 per share. Notably, the stock has gained 1.67% in the last 24 hours and an impressive 11.05% over the past week, demonstrating substantial positive momentum. Over a one-year horizon, the share has appreciated by 22.16%, reflecting strong investor confidence even amidst broader market fluctuations. Recent quarterly results beat analyst expectations, with quarterly revenue climbing to ₹5,592 crores (up 13% YoY) and net profit surging to ₹414 crores (up 54% YoY). These robust figures were propelled not only by organic hospital growth but also by strategic moves such as the announced digital health and pharmacy spin-off and targeted geographic expansion in North India. This strong operational delivery is further supported by favourable sector dynamics: the Indian healthcare market is expanding, private healthcare demand is rising steadily, and demographic trends remain supportive. Apollo Hospitals’s sustained focus on quality, innovation, and technology places it at the centre of these bullish secular trends.
Technical analysis
Technical signals are clearly aligned in favour of Apollo Hospitals’s continued upward movement. The 14-day RSI stands at 65.35, hovering in bullish territory without yet being overbought, suggesting that upside potential persists. The MACD, at 82.06, remains in a buy zone, and the share price has consistently maintained levels above its short- and long-term moving averages (20-day: ₹7,494.70; 50-day: ₹7,285.78; 100-day: ₹7,154.49; and 200-day: ₹7,045.94). Importantly, the stock is holding above key support zones between ₹7,440 and ₹7,470, while technical resistance is forming just above ₹7,600. The “Strong Buy” signal—evidenced by 11 of 12 moving averages in favour—confirms vigorous institutional and retail flows. This technical structure suggests that Apollo Hospitals could be entering a new bullish phase, making it attractive both to trend-following traders and long-term growth investors.
Fundamental analysis
From a fundamental standpoint, Apollo Hospitals exhibits all the hallmarks of an industry leader. Annual revenue surpassed ₹21,150 crores (FY25 annualised), while annual EBITDA reached ₹3,060 crores, highlighting stable profitability and operational efficiency. Net profits have expanded rapidly, underpinned by top-line growth, margin expansion, and an ongoing commitment to cost optimisation. Valuation remains elevated, with a P/E Ratio of 75.2, which is justifiable within the context of the company’s best-in-class growth rate and premium positioning in the Indian private healthcare sector. Dividend yield is modest at 0.21%, reflecting a reinvesting stance that prioritises future growth over cash distribution, which further underlines management’s confidence in the business model. Strategically, Apollo Hospitals is unmatched in its breadth: its network now spans 73 hospitals, commanding a dominant share in tertiary care, and the company retains a strong foothold in high-value markets. It leads in digital healthcare adoption, AI implementation, and continues to expand via both organic and inorganic means (such as the Nova Specialty Hospitals acquisition). Innovation, market leadership, and a powerful brand act as formidable moats, signalling that Apollo Hospitals has built a long-term, resilient foundation for growth.
Volume and liquidity
Sustained trading activity also points to a supportive market structure. The stock’s average 3-month trading volume stands at 453,300 shares, indicating robust liquidity and reflecting active participation by both institutional and retail investors. High liquidity not only ensures favourable entry/exit points for investors but also allows for dynamic price discovery and rapid response to market news. The stock’s freely-traded float is efficiently structured, contributing to healthy turnover and, by extension, supportive valuations that are less prone to manipulation or abnormal volatility.
Catalysts and positive outlook
- Digital health and pharmacy spin-off: The upcoming demerger into a NewCo focused on digital health and pharmacy is expected within 18–21 months. This move will unlock further value, highlight each unit’s competitive edge, and increase flexibility for innovation and new partnerships.
- Geographic and capacity expansion: Ongoing plans to add 3,500–4,300 beds—especially targeting India’s fast-growing northern region—will reinforce network effects, market share, and long-term top-line growth.
- AI and technology investments: Strategic partnership with Microsoft and implementation of four AI copilots mark Apollo Hospitals as a tech-forward leader. This focus will enhance patient outcomes, operational efficiency, and digital revenue streams.
- Favourable macro and sectoral trends: Robust middle-class growth, greater insurance penetration, and rising age demographics are all tailwinds for escalated private healthcare spending in India.
- ESG and compliance leadership: Apollo’s commitment to ethical medical practices, sustainability, and community engagement continues to strengthen its institutional reputation and supports premium valuation.
Combined, these catalysts paint a scenario of accelerating revenue growth, operational optimisation, expansion into new business models, and overall increased sector leadership.
Investment strategies
- Short-term: Strong technical momentum, recent outperformance, and proximity to support levels may offer timely trading opportunities, especially if the stock breaks recent resistance near ₹7,630.
- Medium-term: Approaching spin-off events, quarterly earnings, and progress on hospital expansions are expected to be catalysts that incrementally unlock further value.
- Long-term: Structural thematic drivers—booming demand for healthcare, demographic tailwinds, cutting-edge technology adoption—should bolster Apollo Hospitals’s compounded returns over the coming years. Ideal positioning may involve staged entry points to take advantage of near-term technical support as well as upcoming strategic events likely to re-rate the stock positively.
Is it the right time to buy Apollo Hospitals?
All indicators suggest that Apollo Hospitals now represents a compelling addition to an Indian-focused equity portfolio. The stock combines premium growth with resilient fundamentals: sustained double-digit revenue increases, expansion of operational margins, digital leadership, and broad institutional backing. Liquidity remains ample, valuation is justified by sector-leading growth, and an array of upcoming catalysts—including the anticipated spin-off and nationwide expansion—continue to inspire confidence in the stock’s ability to deliver superior risk-adjusted returns. Given this confluence of strong technicals, robust financial health, and a strategic vision absolutely in step with India’s evolving healthcare needs, Apollo Hospitals seems to represent an excellent opportunity for investors aiming to capture the ongoing transformation of the Indian healthcare landscape. Apollo Hospitals is undeniably entering a new growth phase, and, with multiple value-unlocking initiatives on the horizon, the stock’s upside potential is difficult to ignore for any serious investor looking for strength, innovation, and long-term leadership in the healthcare sector.
How to Buy Apollo Hospitals Stock
Buying Apollo Hospitals stock online is both simple and secure when you use a regulated broker in India. Investors have two main options: purchasing the shares outright (spot buying) or trading Apollo Hospitals via Contracts for Difference (CFDs), which allow leveraged positions without actually owning the stock. Each method offers distinct benefits regarding costs and flexibility. To help you choose the right approach, we provide a broker comparison tool further down the page.
Spot buying
A cash purchase of Apollo Hospitals stock means buying real shares and becoming a direct shareholder. This classic investment method involves paying a fixed brokerage fee for each transaction, commonly ranging from ₹20 to ₹50 per order with leading Indian brokers.
Gain scenario
For example, if Apollo Hospitals share price is ₹7,565, you can buy around 13 shares with a $1,000 investment (about ₹83,000), including a ₹400 (around $5) brokerage fee.
If the share price rises by 10%, your holding is now worth $1,100.
Result: +$100 gross gain, i.e. +10% on your investment.
Trading via CFD
CFD (Contract for Difference) trading on Apollo Hospitals shares allows you to speculate on price changes without owning the actual shares. Instead of a commission, you typically pay the spread (difference between buy and sell price) and possible overnight financing fees if you hold positions for several days. CFDs enable the use of leverage, meaning you can open a larger position for a smaller upfront commitment.
CFD Trading Example: Gain Scenario
You open a CFD position on Apollo Hospitals shares, with 5x leverage and a $1,000 deposit, giving you $5,000 market exposure.
✔️ Gain scenario: If the stock rises by 8%, your position gains 8% × 5 = 40%. Result: +$400 gain on your original $1,000 (excluding fees).
Final advice
Before making any investment decision, compare brokers’ fees, trading conditions, and platforms to find the option best suited to your needs. Whether you choose spot buying for simplicity and long-term ownership, or CFDs for greater flexibility and leverage, your choice should reflect your investment goals and risk profile. You will find a comprehensive broker comparison further down this page to help guide your decision.
Check out the best brokers in India!Compare brokersOur 7 tips for buying Apollo Hospitals stock
| 📊 Step | 📝 Specific tip for Apollo Hospitals |
|---|---|
| Analyze the market | Review Apollo Hospitals recent financial results and strong sector growth in India to identify favourable entry points. |
| Choose the right trading platform | Select a SEBI-registered broker that gives access to NSE/BSE for secure and efficient Apollo Hospitals transactions. |
| Define your investment budget | Decide your exposure based on Apollo Hospitals’ share price and your risk appetite, keeping diversification in mind. |
| Choose a strategy (short or long term) | For Apollo Hospitals, a long-term approach can capture growth from digital health spin-offs and network expansion. |
| Monitor news and financial results | Track quarterly results, major partnerships, and announcements about Apollo Hospitals’ hospital network or digital ventures. |
| Use risk management tools | Utilise stop-loss orders and position sizing to protect gains and manage potential downside in Apollo Hospitals. |
| Sell at the right time | Consider exiting or taking partial profits when Apollo Hospitals reaches technical resistance or after positive catalysts are priced in. |
The latest news about Apollo Hospitals
Apollo Hospitals shares gained over 11% in one week, signaling strong investor confidence. The stock reached ₹7,565, outpacing both sector and index averages on robust volume. Institutional and retail activity increased following the announcement of expansion and digital health initiatives, reinforcing positive sentiment within India’s healthcare sector.
Q4 FY25 results substantially exceeded analyst estimates, with revenue and earnings growth outperforming expectations. The company reported ₹5,592 crores in quarterly revenue (up 13% YoY) and ₹414 crores in net profit (up 54% YoY). This performance was driven by higher occupancy, improved operational efficiency, and continued growth in the hospital and pharmacy segments. It marked Apollo Hospitals as a leader among Indian healthcare stocks.
Apollo Hospitals announced rapid expansion of capacity, focusing on Northern India over the next several years. A strategic plan to add 3,500 beds will enhance the chain’s national footprint, capturing projected demand growth in under-served regions. This initiative is aligned with government and private sector goals of scaling quality healthcare access across India.
The company formalized a major partnership with Microsoft to integrate AI copilots into clinical and back-office functions. This technological adoption, officially reported within the last week, positions Apollo Hospitals at the forefront of digital transformation in Indian healthcare. The use of advanced AI is expected to optimize patient care and operational processes, creating new efficiencies and reinforcing the group’s innovation leadership.
Market sentiment remains broadly positive with 92% analyst buy recommendations for Apollo Hospitals. Recent upgrades from domestic and global institutions reflect constructive long-term perspectives on revenue growth, margin expansion, and the unique momentum of the Indian private healthcare market, supporting the stock’s premium valuation.
FAQ
What is the latest dividend for Apollo Hospitals stock?
Apollo Hospitals currently pays a dividend. The most recent announced dividend was ₹16 per share, with the payment made in July 2025. The current yield is modest at around 0.21%. The company’s policy historically favours reinvesting profits to support growth and long-term value creation.
What is the forecast for Apollo Hospitals stock in 2025, 2026, and 2027?
Based on current price projections, Apollo Hospitals stock is expected to reach ₹9,835 at the end of 2025, ₹11,347 by end of 2026, and ₹15,130 by end of 2027. The hospital sector remains buoyant in India thanks to robust demand, investment in technology, and expansion plans, which support these growth prospects.
Should I sell my Apollo Hospitals shares?
Holding onto Apollo Hospitals shares may be wise given its strong fundamentals and sector leadership. The stock has delivered consistent long-term growth and benefits from ongoing expansion and innovation. Analysts remain positive, and its strategic initiatives provide resilience even in changing markets. For investors seeking long-term exposure to India’s healthcare sector, retaining shares may suit a growth-oriented strategy.
How are Apollo Hospitals dividends and capital gains taxed in India?
Dividends from Apollo Hospitals are taxed according to your income tax slab in India, with a 10% TDS if annual dividends exceed ₹5,000. Capital gains from the sale of shares held more than one year are taxed at 10% beyond a threshold, making it important to track holding periods for tax efficiency.
What is the latest dividend for Apollo Hospitals stock?
Apollo Hospitals currently pays a dividend. The most recent announced dividend was ₹16 per share, with the payment made in July 2025. The current yield is modest at around 0.21%. The company’s policy historically favours reinvesting profits to support growth and long-term value creation.
What is the forecast for Apollo Hospitals stock in 2025, 2026, and 2027?
Based on current price projections, Apollo Hospitals stock is expected to reach ₹9,835 at the end of 2025, ₹11,347 by end of 2026, and ₹15,130 by end of 2027. The hospital sector remains buoyant in India thanks to robust demand, investment in technology, and expansion plans, which support these growth prospects.
Should I sell my Apollo Hospitals shares?
Holding onto Apollo Hospitals shares may be wise given its strong fundamentals and sector leadership. The stock has delivered consistent long-term growth and benefits from ongoing expansion and innovation. Analysts remain positive, and its strategic initiatives provide resilience even in changing markets. For investors seeking long-term exposure to India’s healthcare sector, retaining shares may suit a growth-oriented strategy.
How are Apollo Hospitals dividends and capital gains taxed in India?
Dividends from Apollo Hospitals are taxed according to your income tax slab in India, with a 10% TDS if annual dividends exceed ₹5,000. Capital gains from the sale of shares held more than one year are taxed at 10% beyond a threshold, making it important to track holding periods for tax efficiency.
On the same topic
